Could a common diabetes drug slow cataracts?

NCT ID NCT07176338

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study looks at whether metformin, a standard diabetes medicine, gets into the lens capsule of the eye and can slow the growth of lens cells that cause cataracts. Researchers will collect blood and lens tissue from 40 people with type 2 diabetes and age-related cataracts who already take metformin. The goal is to measure metformin levels in the lens and see if it reduces lens cell growth in lab tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

metformin

What this could lead to

If successful, this could point toward a way to slow cataract formation in people with diabetes.

What could go wrong

This is a very early, small pilot study (40 people) that only tests cells in a lab, not in the eye. It may not lead to any treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATARACT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract senile cataract type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vienna Institute for Research in Ocular Surgery (VIROS)

    Vienna, 1140, Austria